The Tenzer laboratory (#TenzerLab) focuses on the development, optimization and application of methods for quantitative proteome analysis. (Please visit the ISOQuant project page for further information.) In this context, the "Core Facility Mass Spectrometry" of the Research Center for Immunotherapy (FZI) was established in 2005 and has been continuously expanded and extended since then. Within the framework of the research core "DIASyM", which is funded by the BMBF with a total of €6.8 million, we develop novel data-independent acquisition methods for clinical high-throughput phenotyping and systems medicine. Currently, our lab is equipped with three state-of-the-art timsTOF Pro-2 high-performance mass spectrometry platforms from Bruker and one Orbitrap Exploris 480 platform with FAIMS Pro interface. These platforms are available for quantitative proteome analyses, which are used in many collaborative projects, for example in the DFG priority program SPP1580 "Intracellular Compartments as Places of Pathogen - Host Interaction". In addition, the Tenzer group is engaged in the characterization of proteases in MHC class I restricted antigen processing and the mass spectrometric identification of MHC presented peptides (HUPO-HIPP). Another focus of our research is the characterization of the interaction of nanoparticles with biological media within the DFG Collaborative Research Center SFB 1066.
Univ.-Prof. Dr. rer. nat. Stefan Tenzer
Phone: +49 (0)6131 17-6199